title: Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy: a comparison with steady-state bone marrow and peripheral blood.
abstract: OBJECTIVE
  The present study was designed to compare directly the frequency of circulating LTC-IC and E-LTC-IC mobilized in peripheral blood (PB) after chemotherapy supported by either G-CSF (PB-G) or GM-CSF (PB-GM) in comparison to steady-state bone marrow (BM) and PB (PB-ST) values in the same patients.
  
  
  METHODS
  Long-term cultures (LTC) were performed from 20 patients with malignant lymphoma at saturating cell concentrations to assess bulk progenitor cell production and by limiting dilution assay (LDA) to measure both frequency of LTC-IC and their proliferative and differentiation capacities.
  
  
  RESULTS
  While CFC production in bulk LTC was higher at weeks 3-5 with PB-G than with PB-GM samples, week-5 LTC-IC and week-10 LTC-IC (E-LTC-IC) frequencies were not different using a LDA. However, the number of CFC derived from a single LTC-IC was higher in PB-G patients than in PB-GM patients (p = 0.01). Interestingly, the frequency of LTC-IC per 1 x 10(5) MNC in mobilized PB positively correlated with one-year marrow progenitor cell recovery, in contrast to the number of autografted CD34(+) cells and CFU-GM per kg.
  
  
  CONCLUSIONS
  Both G-CSF and GM-CSF resulted in similar increases in LTC-IC and E-LTC-IC in PB at comparable levels to those present in BM. However, the differentiation capacity of LTC-IC was higher after mobilization with G-CSF than with GM-CSF, suggesting qualitative differences in LTC-IC mobilized with these growth factors.
authors.affiliation: Laboratory of Hematology, Faculty of Medicine and University Hospital of Tours, Tours, France.
authors.forename: Lotfi
authors.initials: L
authors.lastname: Benboubker
authors.forename: Christian
authors.initials: C
authors.lastname: Binet
authors.forename: Guillaume
authors.initials: G
authors.lastname: Cartron
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Bernard
authors.forename: Nathalie
authors.initials: N
authors.lastname: Clement
authors.forename: Martine
authors.initials: M
authors.lastname: Delain
authors.forename: Michel
authors.initials: M
authors.lastname: Degenne
authors.forename: Isabelle
authors.initials: I
authors.lastname: Desbois
authors.forename: Philippe
authors.initials: P
authors.lastname: Colombat
authors.forename: Jorge
authors.initials: J
authors.lastname: Domenech
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001773:Blood Cells / Q000473:pathology; D001854:Bone Marrow Cells / Q000473:pathology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor